178 research outputs found

    Fetal Tachyarrhythmia - Part II: Treatment

    Get PDF
    The decision to initiate pharmacological intervention in case of fetal tachycardia depends on several factors and must be weighed against possible maternal and/or fetal adverse effects inherent to the use of antiarrhythmics. First, the seriousness of the fetal condition must be recognized. Many studies have shown that in case of fetal tachycardia, there is a significant predisposition to congestive heart failure and subsequent development of fetal hydrops and even sudden cardiac death1,2,3 Secondly, predictors of congestive heart failure have been suggested in several studies, such as the percentage of time that the tachycardia is present, the gestational age at which the tachycardia occurs4, the ventricular rate5 and the site of origin of the tachycardia6. However, the sensitivity of these predictors is low and they are therefore clinically not very useful. In addition, hemodynamic compromise may occur in less than 24 - 48 hours as has been shown in the fetal lamb7 and in tachycardic fetuses8,9. On the other hand, spontaneous resolution of the tachycardia has also been described10. Thirdly, transplacental management of fetuses with tricuspid regurgitation11, congestive heart failure or fetal hydrops is difficult12,13, probably as a result of limited transplacental transfer of the antiarrhythmic drug14,15. In case of fetal hydrops, conversion rates are decreased and time to conversion is increased13. Treatment of sustained fetal tachycardia is therefore to be preferred above expectant management, although some centers oppose this regimen and suggest that in cases with (intermittent) fetal SVT not complicated by congestive heart failure or fetal hydrops, conservative management and close surveillance might be a reasonable alternative16,17,18

    Fetal Tachyarrhythmia - Part I: Diagnosis

    Get PDF
    Fetal tachycardia, first recognized in 1930 by Hyman et al1, is a condition occurring in approximately 0.4-0.6% of all pregnancies2. A subset of these cases with more sustained periods of tachycardia is clinically relevant. The necessity of therapeutic intervention in this condition is still a matter of discussion focused on the natural history of the disease. The spectrum of opinions varies from non-intervention3,4,5 based on a number of cases in which the tachycardia subsided spontaneously6, to aggressive pharmacotherapeutic intervention7,8 based on reports of deterioration of the fetal condition ultimately ending in significant neurological morbidity9,10,11, or fetal demise12,13,14. Prenatal treatment through indirect, maternally administered drug therapy seems to be the preference of most centers15,16,17,18,19,20,21. This matter will be discussed further in Fetal Tachyarrhythmia, Part II, Treatment

    Fetal tachycardia : diagnosis and treatment

    Get PDF
    Part I: Fetal tachyarrhythmias Diagnosis Fetal tachycardia is a serious condition warranting specialized evaluation. In chapter 2, methods of diagnosis of fetal tachycardia are described, including doppler and M-mode echocardiography and fetal magnetocardiography. The study presented in chapter 3 describes a method for further delineation in the classification of fetal SVT in short and long VA tachyarrhythmias. Consequences Tachyarrhythmia is associated with fetal hydrops. As outlined in chapter 4 and 5, predisposing factors for the development of hydrops seem to be the percentage of time that the tachycardia is present, the gestational age at which the tachycardia occurs, the ventricular rate and the site of origin of the tachycardia. In fetal hydrops, the fetus is at risk for neurological morbidity. In chapter 4, the outcome of 11 fetuses with hydrops as a result of tachyarrhythmia is presented. Treatment In the chapters 3, 4 and 7, it is outlined that transplacental treatment is to be preferred above expectant management. The issue of direct fetal therapy is described in chapter 5 and a review of the literature on the various regimens of drugs used in the transplacental treatment of fetal tachycardia is presented. Chapter 6 describes the pharmacokinetics and pharmacodynamics of sotalol in pregnancy. The overall success rate of sotalol as a single therapy in the treatment of atrial flutter in the studies presented in chapters 6 and 7, was 63 %, and reached 79 % after the addition of digoxin. The success rates in fetal SVT were 53 % and 74 %, respectively. In the SVT group, there were however, four deaths. Low initiation dosages of sotalol, stepwise dosage increases and close monitoring, especially during the initiation phase are recommended. Protocol in the treatment of fetal tachycardia In fetal AF, sotalol, with digoxin as a second line drug, should be the treatment of choice (Figure 1). In nonhydropic fetal SVT, a definite clinical advantage of sotalol over other drugs could not be proved. The treatment protocol (Figure 2) therefore shows 2 options. In fetal SVT complicated by hydrops, two options are proposed: flecainide, or a combination of intravenous digoxin and amiodarone (Figure 3). In conclusion, as a result of the studies of this thesis and of the latest international literature, new treatment protocols are proposed and presented. Part II: Fetal ECG in labour, aspects of the intrapartum QT interval In chapter 9, observations on the intrapartum fetal QT interval in three premature sheep fetuses and one human fetus at term, all being exposed to acute and severe asphyxia, are presented. A shortening of the QT interval is present, shortly after the fetus is exposed to asphyxia, in association with a rise in T/QRS ratio and an increase in blood pressure. In chapter 10, the QT interval in 68 fetuses with signs of severe intrapartum hypoxia also showed a significant shortening of the QT interval. The fetal QT interval during labour may therefore provide additional information on the condition of the fetus

    Феномен мастурбации: негативное или позитивное явление?

    Get PDF
    Рассмотрены разные взгляды на роль мастурбации в становлении сексуальности человека. Представлены результаты собственных исследований автора, проведенных с целью установить значение этого феномена для формирования сексуального поведения и сексуального здоровья.Various opinions about the role of masturbation in human sexuality development are discussed. The findings of the original research performed to evaluate the significance of this phenomenon in formation of sexual behavior and sexual health are reported

    Few randomized trials in preterm birth prevention meet predefined usefulness criteria

    Get PDF
    Funding Information: Funding: The study was funded by a grant from the Netherlands Organization for Health Research and Development (ZonMw Rubicon grand #452182306). The funder had no involvement in any phase of this study. Meta-Research Innovation Center at Stanford (METRICS), Stanford University is supported by a grant from the Laura and John Arnold Foundation. JvtH is supported by postdoctoral grant from the Netherlands Organization for Health Research and Development (Rubicon grand 452,182,306). C.A. is supported by postdoctoral grants from the Knut and Alice Wallenberg Foundation (K.A.W. 2019.0561), Uppsala University, and the Sweden-America Foundation. B.M. is supported by an NHMRC Investigator grant (GNT1176437). B.M. reports consultancy for Guerbet, has been a member of the ObsEva advisory board and holds Stock options for ObsEva. The work of J.I. has been supported by an unrestricted gift from Sue and Bob O'Donnell. J.I. is a team member of the editorial board of JCE. Publisher Copyright: © 2023 The AuthorsPeer reviewe

    Assessing the usefulness of randomised trials in obstetrics and gynaecology

    Get PDF
    FUNDING INFORMATION The study was funded by a grant from the Netherlands Organization for Health Research and Development (ZonMw Rubicon grant #452182306). The funder had no involvement in any phase of this study.Non peer reviewedPublisher PD

    Периоды апробации метода прогноза интегральной метанообильности шахты

    Get PDF
    Розроблені аналітичній та натурній методи урахування метанового потенціалу вугільних шахт, апробація яких в умовах діючих об’єктів вдовж 5 термінів (1967 – 2009 рр.) показала високу надійність метода прогнозу інтегральної метанообільності шахт ІМА (~9 тис. порівнянь). На базі цього методу пропонується розробить державний нормативний документ для урахування метанового потенціалу вугільних шахт та реалізувати науково-технічні проекти авторів, які включені в програму науково-технічного розвитку Донецької області до 2020 р.Analytic and nature methods of calculation of methane potential of the collieries which check in the conditions of operating objects during 5 periods (1967 – 2009 years) has shown high reliability concerning of the method integrated methane of abundance of object IMA (~9 000 results) are developed. On the basis of this method it is offered to develop the state standard document for calculation of methane potential of collieries and to realize author’s projects to be conclusion to the science-technical program of development of Donetsk region to 2020 year

    TBX2, a Novel Regulator of Labour

    Get PDF
    Background and Objectives: Therapeutic interventions targeting molecular factors involved in the transition from uterine quiescence to overt labour are not substantially reducing the rate of spontaneous preterm labour. The identification of novel rational therapeutic targets are essential to prevent the most common cause of neonatal mortality. Based on our previous work showing that Tbx2 (T-Box transcription factor 2) is a putative upstream regulator preceding progesterone withdrawal in mouse myometrium, we now investigate the role of TBX2 in human myometrium. Materials and Methods: RNA microarray analysis of (A) preterm human myometrium samples and (B) myometrial cells overexpressing TBX2 in vitro, combined with subsequent analysis of the two publicly available datasets of (C) Chan et al. and (D) Sharp et al. The effect of TBX2 overexpression on cytokines/chemokines secreted to the myometrium cell culture medium were determined by Luminex assay. Results: Analysis shows that overexpression of TBX2 in myometrial cells results in downregulation of TNFα- and interferon signalling. This downregulation is consistent with the decreased expression of cytokines and chemokines of which a subset has been previously associated with the inflammatory pathways relevant for human labour. In contrast, CXCL5 (C-X-C motif chemokine ligand 5), CCL21 and IL-6 (Interleukin 6), previously reported in relation to parturition, do not seem to be under TBX2 control. The combined bioinformatical analysis of the four mRNA datasets identifies a subset of upstream regulators common to both preterm and term labour under control of TBX2. Surprisingly, TBX2 mRNA levels are increased in preterm contractile myometrium. Conclusions: We identified a subset of upstream regulators common to both preterm and term labour that are activated in labour and repressed by TBX2. The increased TBX2 mRNA expression in myometrium collected during a preterm caesarean section while in spontaneous preterm labour compared to tissue harvested during iatrogenic preterm delivery does not fit the bioinformatical model. We can only explain this by speculating that the in vivo activity of TBX2 in human myometrium depends not only on the TBX2 expression levels but also on levels of the accessory proteins necessary for TBX2 activity

    Nationwide implementation of a decision aid on vaginal birth after cesarean:a before and after cohort study

    Get PDF
    Woman with a history of a previous cesarean section (CS) can choose between an elective repeat CS (ERCS) and a trial of labor (TOL), which can end in a vaginal birth after cesarean (VBAC) or an unplanned CS. Guidelines describe women's rights to make an informed decision between an ERCS or a TOL. However, the rates of TOL and vaginal birth after CS varies greatly between and within countries. The objective of this study is to asses nation-wide implementation of counselling with a decision aid (DA) including a prediction model, on intended delivery compared to care as usual. We hypothesize that this may result in a reduction in practice variation without an increase in cesarean rates or complications. In a multicenter controlled before and after cohort study we evaluate the effect of nation-wide implementation of a DA. Practice variation was defined as the standard deviation (SD) of TOL percentages. A total of 27 hospitals and 1,364 women were included. A significant decrease was found in practice variation (SD TOL rates: 0.17 control group vs. 0.10 intervention group following decision aid implementation, p=0.011). There was no significant difference in the ERCS rate or overall CS rates. A 21% reduction in the combined maternal and perinatal adverse outcomes was seen. Nationwide implementation of the DA showed a significant reduction in practice variation without an increase in the rate of cesarean section or complications, suggesting an improvement in equality of care
    corecore